



Embryo/Fetal Doses from SPECT Radiopharmaceuticals

Nazenin İPEK IŞIKCI,¹ Mustafa DEMİR²

¹Department of Computer Engineering, Nişantaşı University, Faculty of Engineering and Architecture, İstanbul-Türkiye

²Department of Nuclear Medicine, İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, İstanbul-Türkiye

OBJECTIVE

The aim of this study is to calculate embryo/fetal doses in pregnant women who received ^{99m}Tc-labeled radiopharmaceuticals for SPECT/CT scan.

METHODS

Embryo/fetal doses were estimated for 74 pregnant women underwent SPECT/CT scan from different regions of Turkey. OLINDA/EXM package program was used for radiation dose calculation from internal emitters, while CT dose was calculated from modified soft-tissue CT dose index.

RESULTS

The highest embryo/fetal dose was found in ^{99m}Tc- methoxy isobutyl isonitrile (MIBI) myocardial perfusion scintigraphy (MPS) as (8.88+5.55=14.43 mGy) from both distinct modes (stress and rest imaging). The embryo/fetal dose from MPS slightly increased to 15.63 mGy with the CT dose contribution. Whereas, ^{99m}Tc- dimercaptosuccinic acid (DMSA) static renal scintigraphy recorded the lowest embryo/fetal dose among the other diagnostic procedures (mean 1.06 mGy).

CONCLUSION

The embryo/fetal doses increased with simultaneous CT scans in nuclear medicine modalities. Questioning pregnancy before scintigraphy is obligatory the first-line strategy to avoid radiation exposure risks.

Keywords: Embryo/fetal dose; fetus dose; International Commission on Radiological Protection 84; SPECT radiopharmaceuticals; ^{99m}Tc radiopharmaceuticals.

Copyright © 2022, Turkish Society for Radiation Oncology

Introduction

Exposure of pregnant women to ionizing radiation during radiological procedures might unintentionally happen in the early months of pregnancy. The hazards from radiation exposure threaten the intact development of the fetus and disturb the rest of family. After radiation exposure, several types of complications and disorders may be manifested latterly like intrauterine growth restriction, prenatal or neonatal death, congenital malformations, and mental retardation.

In the same framework, radiation dose assessment of embryo/fetal has increasingly gained a great concern in nuclear medicine practices through dose computation and risk estimation. In common practice, different types of radioisotopes and wide range of radioactivity are utilized for diagnostic and therapeutic purposes that might exceed the tolerated fetus dose. Hence, developing precise methods to precisely benchmark radiation dose to embryo/fetus are of great importance with respect to the radiation protection legislations. These models should inherently

Received: October 01, 2021

Accepted: April 02, 2022

Online: May 31, 2022

Accessible online at:

www.onkder.org

OPEN ACCESS This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.



Dr. Nazenin İPEK IŞIKCI

Nişantaşı Üniversitesi, Mühendislik ve Mimarlık Fakültesi,

Bilgisayar Mühendisliği Bölümü,

İstanbul-Türkiye

E-mail: nazenin.ipek@nisantasi.edu.tr

take into account the transfer of radionuclides across the placenta, distribution and retention of the radionuclides in embryonal/fetal tissues, growth of the embryo/fetal, and photon irradiation sources in the placenta and maternal blood.[1]

In general, prenatal radiation exposure of approximately 10 mGy might enhance the risk of fetal disorders such as prenatal death, microcephaly, reduced intelligence quotient, organ malformation, mental retardation, intrauterine growth retardation, and childhood cancers. However, it was reported that radiation dose <50 mSv (5 rem) is not associated with fetal anomalies emergence or pregnancy loss.[2] Several local and global radiation protection organizations such as the International Commission on Radiological Protection (ICRP) and the National Council on Radiation Protection and Measurements declared that fetal radiation doses below 100 mGy should not be used as justification for terminating pregnancy.[3] According to the American College of Obstetricians and Gynecologists, potential health risks may arise after cumulative radiation exposure exceeding 50 mSv, depending on the dose and stage of pregnancy.[2]

Since, many radiopharmaceutical agents are in use for the nuclear investigations, the variation in radionuclides biokinetics and excretion rate is impossible to consider within the fetal dose estimation process.[4] However, practical vehicles have been developed for estimating the radiation dose from both internal radiation emitters and CT.

This study was dedicated to calculate fetal absorbed dose in pregnant women subjected to SPECT scan with ^{99m}Tc-labeled radiopharmaceuticals. A further goal was to compare the fetus dose values generated from the mentioned procedures with the risk thresholds reported by ICRP 84.

Materials and Methods

A group of pregnant female patients applied to receive a consultation from the teratologic counseling center. In Turkey, Genetic Research and Diagnosis Center (GETAM) at Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine provides full counseling services to pregnant patients coming from all hospitals over Turkey. Through that, the pregnant women were referred to the medical physics department to estimate the fetal radiation doses.

Between June 2015 and June 2021, embryo/fetal doses of 74 pregnant women underwent SPECT scans were calculated retrospectively. Gestational age

was obtained from patients' specific ultrasound data. Accordingly, 68 (92%) women were in the first trimester of pregnancy and 6 (8%) were in the second trimester of pregnancy.

All pregnant women were asked to bring the essential documents that contain detailed information about the type of procedure. OLINDA/EXM 1.0 software was used to calculate embryo/fetal dose according to the following MIRD schema:

$$D = \bar{A} \times S = A_0 \times \tau \times S \quad (1)$$

where D is absorbed dose in a target organ (mGy), \bar{A} is cumulated activity in a source organ (MBq · h), A_0 is administered activity (MBq), τ is residence time (h), S is dose factor provided in the program ($\frac{\text{mGy}}{\text{MBq} \cdot \text{h}}$).

Individual embryonal/fetal dosimetry is not applicable, as no pre-imaging procedures could be tried for specific dosimetry. Attempt was made to use fetus kinetic data generated from phantom study reported by Russell et al.[5] The early 3-month and 6-month pregnant female model was selected for all calculations and only patients weight was replaced in the program.

A set of equations was used to estimate the CT related dose following SPECT/CT examinations. The calculated dose values from CT were added to that obtained from SPECT and given as a total SPECT/CT embryo/fetal dose in the results section. FetDose V4 computer software was used to compute the fetal absorbed dose.[6,7]

The fetal dose (D_f) from CT scans was calculated using the formula (2) as seen below:

$$D_f = \frac{\left(NUDV_v \times CTDI_{\text{soft tissue}} \times \left[\frac{mAs}{100} \right] \right)}{Pitch} \quad (2)$$

where CTDI is CT dose index and $CTDI_{\text{soft tissue}}$ (mGy/100 mAs) is the $CTDI_{\text{air}}$ to the ICRU muscle ($CTDI_{\text{soft tissue}} = CTDI_{\text{air}} \times 1.07$) used as approximations for the dose to soft tissue within the body and NUDV is the sum of the normalized doses for all 5 mm slabs lying within the scan volume.[2,6]

Results

The distribution of the fetuses in relation to the gestational age of the subjects was shown in Figure 1. About 68 pregnant women among the participants were majorly in the first trimester of pregnancy. The calculated fetal doses for 74 pregnant women undergone nuclear procedures were given in Table 1. ^{99m}Tc-MIBI MPS involving two distinct modes (stress and rest imaging) yielded the highest mean embryo/fetal dose as (8.88+5.55=14.43 mGy) compared to other nuclear medicine procedures. A slight increase in the fetal dose




Fig. 1. Number of fetuses during pregnancy.




Fig. 2. Distribution of embryo/fetal doses according to the number of fetuses

up to 15.63 mGy was observed in MPS SPECT/CT depending on the CT dose contribution. Whereas, ^{99m}Tc -DMSA static renal scintigraphy recorded the lowest embryo/fetal dose among the other diagnostic procedures (mean 1.06 mGy). The average embryo/fetal dose values for 13 pregnant women underwent bone scintigraphy with ^{99m}Tc -MDP were about 5 mGy (range: 3.76–4.70 mGy). In addition, SPECT/CT over abdomen and pelvis led to extra 8 mGy absorbed dose making the total embryo/fetal dose in MDP 12.07 mGy. The most common scintigraphy is thyroid scintigraphy where the embryo/fetal dose range of 35 pregnant patients was 1.86–4.07 mGy with an average of 3.13 mGy. Overall, the participant subjects were categorized according to the absorbed dose intervals as exhibited in Figure 2.

Discussion

Diagnostic and therapeutic nuclear medicine examinations are usually conducted using different radiopharmaceuticals with variable bio-kinetics. To date, ^{99m}Tc is heavily used in the scintigraphy of the main organs like thyroid, lung, liver, kidney, and bone. Pregnant women might unintentionally undergo radiation procedures in the daily practice. The stream of the present study was to quantify and explore the level of radiation dose to the fetus from different kinds of radiopharmaceutical examinations. According to the previous studies, the maternal bladder is the deemed the main source of fetus radiation dose.[8–10] The average fetal from

Table 1 Embryo/fetal doses from nuclear medicine diagnostic examinations

Examination type (radiopharmaceuticals) (activity) (fetus numbers)	Embryo/fetal dose		Gestational age range
	Range (mGy)	Mean (mGy)	Week (w), Day (d)
Bone scintigraphy (Tc MDP) (925–1110 MBq) (n=12)	3.76-5.64	4.41	2w+0d-12w+5d
Renal scintigraphy (^{99m}Tc DTPA) (185–370 MBq) (n=4)	1.53-5.33	2.48	4w+1d-12w+0d
Renal scintigraphy (^{99m}Tc DMSA) (111–185 MBq) (n=5)	0.31-2.77	1.06	2w+4d-12w+0d
Lymphoscintigraphy (^{99m}Tc Nanocolloid) (185–370 MBq) (n=3)	0.15-3.1	1.22	4w+2d-16 w+5d
Myocardial perfusion scintigraphy (Stress+rest (^{99m}Tc MIBI) (1110 MBq) (n=13)	8.88-14.43	11.63	3w+3d-24w+1d
Thyroid scintigraphy (^{99m}Tc Per technetate) (185–370 MBq) (n=35)	1.86-4.07	3.13	2w+4d-21w+1d
SPECT/CT Bone SPECT (^{99m}Tc MDP) (925–1110 MBq) (n=1)	12.07	-	4w 2d
SPECT/CT myocardial perfusion scintigraphy (^{99m}Tc MIBI) (1110 MBq) (n=1)	22.43	-	5w 1d

MBq: Mega becquerel; MDP: Methylene diphosphonate; DTPA: f DMSA: Dimercaptosuccinic acid; MIBI: Methoxy isobutyl isonitrile.

^{99m}Tc -MDP was 4.41 mGy (range: 3.76–5.64 mGy). The embryo/fetal dose was increased to 12 mGy twice the dose from SPECT when SPECT/CT was acquired. In addition, the corresponding radiation dose due to MPS is relatively higher compared to other scintigraphy procedures ranging from 8.88 to 14.43 mGy, taking into account the large amount of activities (e.g., 740+370 MBq for stress and rest imaging). Likewise, it was reported that the fetal dose of a patient administered by 1000 MBq ^{99m}Tc -MIBI is 12 mGy.[11] With adding the CT dose portion, the overall embryo/fetal dose reaches 15.63 mGy which is the highest value among other ^{99m}Tc radiopharmaceuticals.

In contrast, ^{99m}Tc -diethylene triamine pentaacetic acid (DTPA) is rapidly distributed throughout the extracellular fluid space following intravenous injection, while the most of the activity accumulates in the kidneys and excreted out through the urinary bladder. The average dose of embryo/fetal for three pregnant women underwent dynamic renal scintigraphy with ^{99m}Tc -DTPA was 2.48 mGy. In another study, fetal dose values for ^{99m}Tc -DTPA scan were calculated as 1.66 mGy for <3 months of pregnancy.[12] Moreover, 35 patients subjected to thyroid scintigraphy with 185–370 MBq ^{99m}Tc -pertechnetate. The respective fetal dose was 3.13 mGy at 2–21 weeks of gestation. Similarly, embryo/fetal dose was given as 0.8 mGy after administration of 75 MBq ^{99m}Tc -pertechnetate.[13]

On the other hand, ICRP Publication 84 stated that radiation-induced malformation has a threshold of 50–100 mGy (5–10 rad). A serious fetal damage might occur when embryo/fetal doses exceed 500 mGy (50 rad) taking into consideration the radiation type and stage of pregnancy.[3]

Eventually, the diagnostic nuclear medicine examinations often induce fetal dose less than the pregnancy terminating dose threshold (100 mGy) reported by ICRP 84. To be remembered, radiation exposure may develop deterministic and stochastic effects on the fetus. The deterministic effects are dose-correlated and lead to distinct damage or mutations in the fetus DNA genes. However, the stochastic effect has no dose threshold ensuring possible side effects even with small doses.[2] Furthermore, the carcinogenesis risk has a linear correlation and monotonic increase with the radiation dose, and therefore exposure to low dose levels may boost the cancer occurrence risk.[14] Overall, adequate maternal hydration and frequent urination reduce fetal exposure to radionuclides, however, long-term watching after birth still an essential to unveil the stochastic effects after radiation exposure.

To this end, ^{99m}Tc -labelled agents are short lived radiopharmaceuticals and fetal dose exceeding 100 mGy from a single procedure is impossible. Thus, teratogenic consultation is distinctly recommended and medical abortions decision can be made in cooperation with family, obstetrician, and medical physicist.

Conclusion

It was determined that embryo/fetal doses increased with the introduction of SPECT/CT into nuclear medicine applications. The embryo/fetal radiosensitivity is extremely high and therefore questioning women of childbearing age before scintigraphy should be the first-line strategy to avoid radiation exposure toxicities.

Peer-review: Externally peer-reviewed.

Conflict of Interest: All authors declared no conflict of interest.

Ethics Committee Approval: The study was approved by the İstanbul University Cerrahpaşa Faculty of Medicine Ethics Committee (No: 219488, Date: 09/07/2015).

Financial Support: None declared.

Authorship contributions: Concept – N.İ.I., M.D.; Design – N.İ.I.; Supervision – N.İ.I., M.D.; Funding – M.D., N.İ.I.; Data collection and/or processing – M.D., N.İ.I.; Data analysis and/or interpretation – M.D., N.İ.I.; Literature search – M.D., N.İ.I.; Writing – N.İ.I.; Critical review – M.D.

References

1. ICRP Publication 88. International Commission on Radiological Protection. Doses to the embryo and fetus from intakes of radionuclides by the mother. Ann ICRP 2001;31.
2. ACOG Committee on Obstetric Practice. ACOG Committee opinion. Number 299, September 2004 (replaces No. 158, September 1995). Guidelines for diagnostic imaging during pregnancy. Obstet Gynecol 2004;104(3):647–51.
3. ICRP Publication 84. International Commission on Radiological Protection. Pregnancy and medical radiation. Ann ICRP 2000;30.
4. ICRP Publication 106. International Commission on Radiological Protection. Radiation dose to patients from radiopharmaceuticals. Ann ICRP 2008;38:1–2.
5. Russell J R, Stabin M, Sparks RB, Watson E. Radiation absorbed dose to the embryo/fetus from radiopharmaceuticals. Health Physics 1997;73(5):756–69.
6. Ozbayrak M, Cavdar I, Seven M, Uslu Besli L, Yeyin

- N, Tanyildizi H, et al. Determining and managing fetal radiation dose from diagnostic radiology procedures in Turkey. *Korean J Radiol* 2015;16(6):1276–82.
7. Osei EK, Kotre CJ. Equivalent dose to the fetus from occupational exposure of pregnant staff in diagnostic radiology. *Br J Radiol* 2001;74(883):629–37.
 8. ICRP Publication 60. International Commission on Radiological Protection. 1990 recommendations of the ICRP. *Ann ICRP* 1991;21.
 9. McKenzie AF, Budd RS, Yang C, Shapiro B, Hicks RJ. Technetium-99m-methylene diphosphonate uptake in the fetal skeleton at 30 weeks gestation. *J Nuc Med* 1994;35(8):1338–34.
 10. Hedrick WR, Simone RN, Wolf BH, Langer A. Absorbed dose to the fetus during bone scintigraphy. *Radiology* 1988;168(1):245–54.
 11. Stabin MG. Radiation dose and risks to fetus from nuclear medicine procedures. *Physica Medica* 2017;43:190–8.
 12. Arteaga MV, Carrillo HV, Benites CR, Rengifo KM, Garcia AJ, Gomez AR. Absorbed dose in the uterine wall and fetus by ^{99m}Tc administration (DTPA, DMSA and MAG3). *Momento* 2021;62:32–42.
 13. Schaefer C, Meister R, Wentzeck R, Weber-Schoendorfer C. Fetal outcome after technetium scintigraphy in early pregnancy. *Reproductive Toxicology* 2009;28(2):161–6.
 14. Di Leo M, Arcidiacono PG. Fetal radiation exposure: Is monitoring really needed? *World J Gastrointest Endosc* 2013;5(8):366–8.